

Index

A

- 1A (A/B transcript), 90, 91, 93
Abdominal surgery, 283–284
Abnormal facies, 145, 189, 191
Absent type 1 PTH Receptor, 262
A/B transcript, 90, 92–94, 374, 380
Accessory thyroid glands, 3
Acid-base status, 314
Acquired hypoparathyroidism, 141, 143, 161, 232, 271–276, 322
ACRDYS2, 375, 376, 382, 383, 385
Acrodysostosis, 350, 351, 360, 369, 375, 376, 382–384
Activating mutations, 40, 89, 145, 161, 162, 170, 171
Activation frequency, 287, 294
Active transcellular transport, 50, 53
Active vitamin D supplementation, 140, 148, 338
Addison's disease (AD), 142, 143, 168, 177, 178, 183, 227, 280, 281, 328
Adenylate cyclase (AC), 37–39, 64, 65, 70, 102, 103, 120, 364, 365, 373, 377
Adenylate cyclase-cAMP-protein kinase A (PKA), 103
Adenyl cyclase, 364
Adenyl cyclase, 81, 89, 90, 92, 347, 357, 399
Adrenoleukodystrophy of Schilder's disease, 274
Agonist-Driven Insertional Signaling (ADIS), 38, 39
Albright, F., 4, 7, 320, 345, 363–365, 373
Albright's hereditary osteodystrophy (AHO), 89, 162, 345–347, 349–351, 355–361, 363–365, 369, 374, 375, 377, 380, 382
Albumin, 61, 157, 163, 231, 256, 280, 297, 314, 317
Albumin-corrected serum calcium, 249, 253, 314
Albumin-corrected total calcium, 155
Alfacalcidol, 301, 305, 306, 308, 334
Alkaline phosphatase, 55, 100, 239, 251, 322, 325, 338
Alkalosis, 171, 297, 306, 314, 398
Alternatively spliced, 357, 365, 377
Alternative splicing, 20, 90, 111
Alveolar bone, 23
Amiloride, 307
Amino-terminal, 25, 83, 167, 250
Amniotic fluid, 253
Amphipathic α -helix, 82, 83
Amyloidosis, 27, 273
Anabolic effect, 117, 338
Antibiotics, 63, 161, 218, 284
Antibodies, 8, 16, 25, 41, 116, 117, 142, 143, 161, 170, 180, 182, 183, 191, 194, 320, 327, 347, 349
Antibody-dependent cellular cytotoxicity, 184
Anti-parathyroid gland antibodies, 143
Antisense transcript (AS), 91, 92, 374
Antithyroid drugs, 232
Anxiety, 411
Apical calcium channel, 69, 105
Apoptosis, 12, 14, 23, 33, 44, 101, 102, 115–117, 119, 120, 145, 169
APS-1. *See* Autoimmune polyglandular syndrome type 1 (APS-1)
Arachidonic acid (AA), 40, 55, 56
Array-comparative genomic hybridization (array-CGH), 192, 193
Arrestins, 82, 85, 102
Arrhythmia, 27, 140, 156, 157, 259, 309, 316, 400
Atrioventricular heart block, 157
Aurbach, G.D., 4, 8, 364
AU-rich element (ARE), 41, 42
AU-rich factor (AUF-1), 41–42
Autoantibodies, 143, 177–186
Autograft, 135, 237–238, 241, 242
Autoimmune
 diseases, 139, 162, 185, 191, 192, 271, 279, 281
 hemolytic anemia, 191
 hypoparathyroidism, 140, 142–143, 150, 160, 177–186, 272, 322, 324
 manifestations, 191
Autoimmune polyendocrine syndrome (APS), 280–281
 type 1 (APS-1), 142, 143, 158–160, 177–186, 319–323, 325, 327, 328
 type 2 (APS2), 177–179, 181, 182, 281
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), 8, 142, 177, 279–281, 320
Autoimmune polyglandular syndrome type 1 (APS-1), 142, 143, 158–160, 177–186, 319–323, 325, 327, 328, 333
Autoimmune regulator (AIRE) gene, 8, 142, 144, 160, 177, 178, 185, 186, 281
Autosomal dominant, 144–146, 160, 162, 167, 169, 171, 172, 192, 215, 218, 226, 262, 276, 284, 345, 350, 365–367
Autosomal dominant disease/disorder, 159, 215, 357, 393

- Autosomal dominant hypocalcemia (ADH), 8–9, 144, 170, 171, 282, 333
 type 1 (ADH1), 144, 168–171
 type 2 (ADH2), 145, 168–171
- Autosomal dominant hypocalcemic hypercalciuria, 64
- Autosomal dominant hypophosphatemic rickets (ADHR), 72
- Autosomal dominant mode of inheritance, 169, 284, 365
- Autosomal recessive, 142, 144, 145, 160, 167, 171, 172, 177, 178, 215, 218, 221, 226, 326, 389, 390, 397
- Autosomal recessive hypoparathyroidism, 145, 169, 199
- Autotransplantation, 142, 237, 238, 242
 of parathyroid tissue, 233
- B**
- Baber, E.C., 5
- Bartter syndrome subtype V, 169, 171
- Basal ganglia, 148, 156, 160, 162, 333
- Basal ganglia calcifications (BGC), 148–149, 156, 160, 162, 171, 209, 307, 316, 347, 357
- Basic helix loop helix (bHLH) transcription factor, 103–104
- Basolateral membrane, 69–71, 171, 347, 398
- Beckwith-Wiedemann syndrome, 384
- β -catenin, 102, 132
- Beta cells, 23
- β -thalassemia, 143
- β -tubulin, 219, 220
- Biallelically expressed, 91, 92, 357, 358
- Biallelic, $Gs\alpha$ expression, 92
- Bicarbonate, 61, 103, 314, 315
- Billing data, 146
- Biochemical markers
 of bone resorption, 251, 293
 of bone turnover, 292, 337
- Bisphosphonates, 260, 275
- Blomstrand chondrodysplasia (BOCD), 100, 114, 262, 389–394
- Blood
 calcium, 6, 7, 23, 81, 167, 190, 249, 252, 255, 256, 258–261, 316, 319, 329
 transfusion, 194, 274
 vessels, 21, 129, 142, 219
- Blood pressure, 23, 114, 121, 159, 298, 306, 316, 408
- BMD. *See* Bone mineral density (BMD)
- BMI, 216, 347
- BMP4, 13, 14, 55
- BOCD. *See* Blomstrand chondrodysplasia (BOCD)
- Bone
 alkaline phosphatase, 239
 aluminum staining, 274
 formation rate, 149, 287, 288, 292, 338
 markers, 322, 325
 mass, 101, 149, 162, 251, 255, 275, 287, 290, 293–295, 326
 matrix, 69, 70, 72, 102, 295
 remodeling unit, 294
 remodelling, 50, 149, 287, 288, 290, 294, 295, 326, 348, 390
 resorption, 22, 23, 35, 70, 71, 75, 76, 99, 101, 102, 157, 232, 250, 251, 253–255, 258, 262, 283, 287, 290, 292, 293, 308, 347, 369, 394
 resorption markers, 254
 resorption rate, 290, 292
 turnover, 27, 28, 35, 51–54, 69, 99, 101, 149, 162, 239, 242, 254, 256, 257, 260, 279, 283, 290–292, 303, 304, 321–325, 333, 337, 338, 369
- Bone marrow, 100, 102, 116–119, 135, 274
- Bone mineral density (BMD), 27, 162, 251, 253, 275, 303, 316, 324–326, 337, 348, 349, 357, 389, 392
- Bone mineral density (BMD) Z score, 325, 326
- Boothby, W.M., 5–7
- Bosentan, 43
- Bovine endothelial cells, 180
- Bovine parathyroid, 38, 40, 129–131, 133–135, 180
- Brachioradial muscle of non-dominant forearm, 242
- Brachydactyly, 262, 345, 347, 351, 355–357, 360, 363, 369, 375, 376, 382
- Brachydactyly mental retardation syndrome (BDMR), 350, 351
- Bradycardia, 157
- Branching morphogenesis, 23
- Breastfeeding, 253, 254, 257, 258, 308
- Breast milk, 253–255, 259, 262
- Breast milk calcium, 253
- Breasts, 23, 111, 112, 117, 250, 253–258, 260
- Bronchospasm, 146, 155, 156, 159, 233, 313
- Brown adipose tissue, 94
- Brown tumors, 239
- Burn injuries, 271, 275
- C**
- Calbindin D28K, 105
- 1 α -Calcidiol, 257, 258
- Calciferol, 280, 305, 306, 309
- Calciferol steroid therapy, 280
- Calcification, 115, 148, 149, 162, 201, 307, 315, 316, 345, 355
- Calcilytics, 171
- Calcimimetic CaSR activators, 39
- Calcineurin inhibitors, 63
- Calcitonin, 21, 82, 103, 135, 143, 232, 250–255, 309, 346, 349, 351, 369, 374, 384
- Calcitonin-secreting cells (C cells), 21
- Calcitriol, 53, 55, 73, 132, 162, 170, 249, 250, 252, 253, 255–259, 288, 300, 301, 305, 306, 308, 315, 319–326, 328, 397, 398
- Calcium
 deprivation, 271, 275
 excretion, 144, 147, 158, 170, 232, 251, 253, 257, 301, 303, 306, 309, 313–315, 320, 321, 324–327, 336–337, 366

- homeostasis, 22, 65, 81, 232, 236, 250, 262, 303, 308–310, 321, 324, 325, 363, 409
and magnesium supplementation, 319
metabolism, 5, 6, 251, 254–255, 262, 351
supplementation/supplements, 73, 141, 195, 272, 288, 300, 301, 303–305, 308, 309, 315, 321–323, 326–328, 334–335
transport, 23, 105, 112, 250, 252, 258, 275, 319
and vitamin D supplementation, 333
- Calcium (Ca^{2+})
absorption, 35
homeostasis, 69
- Calcium carbonate, 300, 304
- Calcium gluconate, 283, 299, 300, 308, 313
- Calcium homeostasis feedback loop, 409
- Calcium-phosphate product, 314, 315, 337
- Calcium-phosphorus product, 303, 305, 307
- Calcium sensing receptor (CaSR), 9, 14, 21, 23, 27, 37–44, 53–57, 64, 65, 70, 74–76, 129–132, 134, 135, 140, 142–145, 149, 156–158, 160–162, 167–172, 180–186, 210, 232, 261, 275, 276, 279, 282–284, 293, 314, 315, 319, 320, 322–326, 328, 397, 398, 400
activating mutation in, 9, 37, 39–40, 64, 158, 160–162, 171, 261, 279, 282–283, 314, 319, 320, 322
autoantibodies, 143, 181, 183, 184, 186
database, www.casrdb.mcgill.ca/; 21, 22, 170
inactivating mutations of, 39–40, 64
mRNA, 130, 134
- Calcium x phosphate product, 146
- Calmodulin (CaM), 42, 69, 105
- cAMP/PKA, 81, 82, 85, 103, 374
- Cancellous bone, 287, 290, 291, 293, 337
- Cancellous bone volume, 27, 149, 287–291, 293
- Cancellous mineralizing surface, 291
- Candidiasis, 142, 158, 159, 177, 178, 281
- Canonical wnt signaling, 102
- Ca^{2+} , homeostasis, 33–36
- Carboxyl-terminal, 21, 25, 28, 250
- Carboxyl-terminal fragments/C-terminal fragments, 21, 25, 28, 250
- Cardiac abnormality (especially tetralogy of Fallot), 191
- Cardiomyocytes, 115, 116
- Carpopedal cramps, 233
- Carpopedal spasm, 159, 170, 227, 297, 298
- CaSR. *See* Calcium sensing receptor (CaSR)
- CaSR-transfected, 38, 183
- Cataracts, 149, 156, 201, 226, 298, 305, 307, 316, 347, 357, 389, 392
- Catecholamine, 84, 374
- Cathelicidin, 121
- Cathepsins, 26
- Cathepsins D and H, 41
- Cation, 61, 63, 373, 397, 398
- Caveolae, 105
- Ca^{++} Pi product, 73–76
- C cells. *See* Calcitonin-secreting cells (C cells)
- Ccl21, 14, 15
- CD73, 135
- CD105, 135
- CD8⁺ cytotoxic T cells, 185
- Celiac disease, 281–282
- Cell signalling, 49
- Cell-specific imprinting, 347
- Cellular (T-cell) immunity, 189
- Centrosomes, 220
- Cervical surgery, 231
- Chaperone, 105, 169, 220
- Chaperone E gene, 218, 221
- Characteristic facies, 189
- Characteristic lymphocytic infiltration, 179
- Cholecalciferol, 71, 227, 257, 258, 300, 305, 322–324, 327, 333, 361
- Cholecystokinin, 40
- Chondrocyte maturation, 23
- Chondrocytes, 21, 23, 99–100, 135, 360, 374, 383, 390, 392, 393
- Chromosomal rearrangements, 189
- Chromosome 22, 189, 191, 192
- Chromosome 11p15, 19, 20
- Chromosome 20q, 368, 375, 381, 384
- Chromosome 20q13, 365
- Chromosome 20q13.3, 345, 367
- Chromosome 22q11, 145, 160, 200
- Chronic kidney disease (CKD), 39, 53, 55, 56, 72, 121, 129, 134, 147, 242, 315, 322, 337
- Chronic mucocutaneous candidiasis, 177
- Chronic renal failure, 161, 281
- Chvostek, 298
- Chvostek's sign, 156, 159, 233, 298
- Cinacalcet, 38, 39, 41, 44, 275, 398, 400
- Circulating molecular forms of PTH, 25, 28
- Circumoral tingling and numbness, 233
- Citrate, 61, 297, 300, 304
- Clathrin, 85
- Clathrin-coated pits, 70
- Claudin-16, 62–64
- Claudin-19, 62–64
- Claudins, 71
- Cleft palate, 145, 157, 191, 194, 195
- Clinical features, 189–191, 208, 209, 215, 225, 226, 228, 346, 349, 350, 355–357, 389–392
- Clonal rat cell line, 130
- Cloning of the receptor for the hormone, 8
- Cochlear abnormalities, 210
- Cognitive dysfunction, 148, 303, 383
- Collagen cross-links, 295
- Collecting ducts, 70, 170, 283
- Collip, J.B., 4, 6, 7, 320
- Colon, 61, 112
- Comorbidities, 148, 149, 157, 304, 409
- Comparative genomic hybridization, 381
- Complement-fixation, 184
- Complications, 27, 62, 139, 140, 146–149, 156, 218, 219, 231, 239, 241, 256, 259, 280, 282, 283, 299, 303, 309, 310, 313–316, 319, 337, 361
- Compound heterozygous inactivating mutations, 389

- Computed tomography (CT), 162, 163, 315, 316
 brain, 162
 Congenital heart defects, 145, 189, 190
 Congenital heart disease, 189
 Congenital hypoparathyroidism, 218, 322, 325, 326, 329
 Congestive heart failure, 116, 155, 156, 233
 Connecting tubules, 105
 Consanguineous family, 169, 215
 Consanguineous parents, 390, 393
 Constitutively active PTHR1, 100, 101
 Constitutive PTHR1 signaling, 85
 Continuous infusion, 101, 300
 Conventional treatment, 279, 280, 303–310, 319, 321,
 322, 325, 326, 329, 334, 341
 Convulsions, 140, 190, 275, 276, 347
 Copper accumulation, 274
 Cortical porosity, 288, 293, 338–340
 Cortical TAL (cTAL), 64
 Cortical thick ascending limb, 34, 319, 398
 Cortical width, 27, 149, 288, 293, 339
 Corticosteroid therapy, 272, 273
 Corticotrophin-releasing factor (CRF), 82, 84, 365
 Cost of caring, 146
 C-PTH fragments, 26–28
 Craig, L., 8
 Creatinine clearance, 147, 158, 315, 322
 CREB, 81, 373
 Cryptorchidism, 205, 216
 Crystallographic structures, 84
 Crystallographic study, 206
 CTLA-4, 185
 Cyclic adenosine monophosphate (cAMP), 39, 51, 52,
 64, 65, 81, 85, 89, 90, 103–105, 115–117,
 120, 132, 171, 200, 345, 347–351, 357–360,
 364, 366, 369, 373, 374, 377, 382, 383, 392,
 393, 399
 Cyclin D1, 43
 Cyclin dependent kinase, 43, 56
 CYP24A1, 71, 74, 252
 Cyp27B1, 51–54, 70–72, 74, 103–104, 250, 252, 253,
 255–257
 Cytokinesis, 220
 Cytoplasm, 37, 111, 112
 Cytoskeleton, 40, 85, 104, 221
 Cytotoxicity assays, 180
 Cytotoxic T-lymphocytes, 191
- D**
 DCT. *See* Distal convoluted tubule (DCT)
 Deafness, 64, 144, 146, 159, 172, 199–210, 227, 228
 Decreased absorption, increased losses, 62
 Decreased intake, 62, 282
 Deficits in mental and physical functioning, 335
 Degradation, 26, 27, 33, 37, 41, 42, 70, 71, 74, 90, 102,
 117, 360
 Degradation of PTH, 21, 26, 33, 35–37, 41, 42, 44, 70
 Degradative, 26
 7-Dehydrocholesterol, 71
 Deletions, chromosome 10p, 200
 Deletions/insertions, Gs α mutations, 364
 Dentin matrix protein-1 (DMP-1), 51, 72, 101
 Depression, 4, 156, 157, 233, 260, 320, 400, 409, 411
 Dermis, 355, 382
 Developmental delay, 199, 216, 355
 Developmental focus, 20
 Diagnosis, 4, 7–9, 28, 139–141, 144, 146, 148, 156–159,
 162, 181, 189–192, 195, 205, 218, 225–228,
 234, 240, 249, 261, 273, 274, 276, 279,
 281–283, 297–298, 345–351, 355, 360, 377,
 380, 382–384, 392, 400, 401, 407–410, 412
 Diaphyses, 215, 219
 Diarrhea, 63, 161, 227, 281, 307, 309, 324, 399–401
 Dietary intake of Mg²⁺, 61
 Dietary phosphate content, 50, 54
 Differentially methylated region (DMR), 90–94, 350,
 360, 367, 369, 374–378, 380, 381, 384, 385
 Differentiation, 11–14, 22, 23, 70, 81, 99, 100, 102, 119,
 135, 143, 172, 200, 209, 210, 279, 360, 373,
 374, 392
 DiGeorge, A., 189, 200
 DiGeorge syndrome (DGS), 27, 144, 145, 156, 157, 159,
 160, 189–195, 200, 218, 261, 287, 333
 Dihydrotachysterol, 305, 306
 1,25-Dihydroxyvitamin D (1,25(OH)₂vitamin D), 26–28,
 70–76, 155, 167, 305, 308–310, 347, 398
 1,25-Dihydroxyvitamin D (1,25(OH)D), 21, 22, 53, 75,
 195, 272, 284, 300, 301, 333, 335, 356, 359
 1,25-Dihydroxyvitamin D₃, 21, 324
 1,25 Dihydroxyvitamin D₃ (1,25(OH)₂D₃), 22, 33–36, 44,
 103–105, 130, 280, 324
 2,3-Diphospho-glycerate, 49
 Disappointing, 4, 27, 320
 Distal convoluted tubule (DCT), 34, 61, 62, 64, 74, 104,
 105, 319, 347, 348, 398, 400
 Distal nephron, 62, 103, 105, 155
 Distal tubules, 70, 74, 103–105, 284, 307, 319, 347,
 361, 366
 Disulfide bonds, 38, 83, 84
 Diuretics, 63, 161, 170, 284, 288, 301, 306, 307, 309,
 315, 321, 327, 398, 400, 401
 DMP-1. *See* Dentin matrix protein-1 (DMP-1)
 DMR. *See* Differentially methylated region (DMR)
 DNA binding, 172, 206–208
 Doppler flow imaging, 232
Drosophila, 12, 171, 220
 DSEL, 85
 Dual energy X-ray absorptiometry (DXA), 162, 163,
 251, 255, 316, 325
 Dunhill procedure, 236, 237
 Duodenum, 50
 Dwarfism, 100, 145, 215–222, 262, 389, 393
 Dysmorphic facial appearance, 191, 326
- E**
 Early-onset obesity, 355–357, 359, 360
 Early postnatal period, 94, 210

- Echocardiogram, 195, 316
 Ectopic ossifications, 347, 355, 358, 360, 361, 363, 375
 EGFR. *See* Epidermal growth factor receptor (EGFR)
 EGFR tyrosine kinase, 43
 Eiken skeletal dysplasia (EISD), 389, 393
 Ekins, R., 8
 Electrocardiogram, 156, 316
 Elemental calcium, 195, 299, 300
 Elevated serum PTH, 346, 356
 ELISA, 183
 Ellsworth-Howard test, 7, 360, 383
 Embryogenesis, 11, 19
 Embryonic development, 11, 100, 172, 193, 194, 199, 200
 Enamel hypoplasia, 156, 178, 216, 316
 Enchondromatosis (ENCHOM), 389, 393
 Endochondral bone development, 23, 252, 260, 382
 Endocortical and intracortical envelopes, 292, 293, 339
 Endocytosis, 70, 105
 Endoplasmic reticulum (ER), 19, 21, 37, 42, 111, 145, 167, 169, 170, 390
 End-organ resistance to PTH, 161, 363
 Endothelin-1 (ET-1), 43
 End-stage renal disease, 28
 Energy metabolic pathways, 49
 Epidermal growth factor receptor (EGFR), 39, 43, 56, 63, 64, 400
 Epidermal growth factor (EGF) receptor antagonists, 63
 Epigenetic mechanism, 121, 374, 384
 Epigenetics, 92, 94, 121, 199, 346, 349, 363, 367, 369, 373–374, 383–384
 Epiphysis, 355
 Epithelial-to-mesenchymal transition, 116, 119–120
 Epsom salts, 64
 Erdheim, J., 5
 Ergocalciferol, 71, 300, 305, 324
 ERK1/2, 39, 40, 43, 73, 74, 82
 Erythrocyte G_sα bioactivity, 360
 Erythrocytes, 346, 350, 360, 364, 380, 383
 Estradiol, 254–258, 347
 Estrogen, 116, 307–308, 310, 357, 359
 Eunuchoidism, 274
 Exocytosis, 19, 36, 37, 40
 Exon A/B methylation, 367
 Exosome, 42
 Expectations for patients with DiGeorge Syndrome, 195
 Experimental thyroidectomy, 5
 Expression cloning, 38
 External irradiation, 271
 Extracellular Ca²⁺, 33–44
 Extracellular Ca²⁺(Ca²⁺_o), 33, 34
 Extracellular calcium-sensing receptor (CaSR), 21, 27, 129, 156, 232
 Extracellular domain (ECD), 21, 38–40, 83–84, 142, 143, 169, 170, 393
 Extracellular domain of the CaSR, 142, 181
 Extracellular domain of the receptor, 142, 181, 183
 Extracellular fluid (ECF), 34, 61, 167, 304, 397, 398, 400
 Extracellular signal-regulated kinase 1/2 (ERK1/2), 39, 73, 82
 Extra-large variant of Gsα, 90
 Extra-large variant of Gsα (XLαs), 90–92, 374, 377
 Extrapyramidal neurological dysfunction, 156
 Extraskeletal calcifications, 303, 307, 333, 337
Eyal, 12
- F**
 FAM111A, 215, 218, 221
 Familial hypocalciuric hypercalcemia (FHH), 64, 259–260, 276, 282, 283
 FHH2, 169
 FHH3, 169
 Familial hypocalciuric hypercalcemia type 1 (FHH1), 169
 Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), 62, 63
 Familial isolated hypoparathyroidism (FIH), 144, 167–172, 333
 Familial PHPT, 241
 Family B GPCRs, 82–84
 Fanconi syndrome, 226, 227
 Femoral neck, 274, 337
 Fetal and adult life, 21
 Fetal and neonatal hypoparathyroidism, 259–262
 Fetal skeleton, 249, 251, 258
 Fetus, 161, 190, 228, 249–252, 255, 258, 260–262, 275, 276, 389–391
 FGF2, 103
 FGF8/10, 10, 13, 14
 FGF23. *See* Fibroblast growth factor 23 (FGF23)
 FGF23/Klotho, 51, 55, 57
 FGFR-1c, 53
 FGFR-Klotho complexes, 74
 Fibroblast growth factor 23 (FGF23), 21, 33, 35, 36, 44, 50, 53, 54, 57, 69–76, 99, 115, 158, 252
 Fibroblast growth factor (FGF), 13, 14, 72–74
 Fibroblast growth factor receptor (FGFR), 72–75
 Fibroblasts, 119, 130–133, 135, 220, 273, 346, 350, 364, 365, 393
 Filtered calcium load, 333, 336, 337
 Filtered load of calcium, 314
 First generation assays, 25, 26, 28
 First generation PTH assays, 28
 Floxed PTHR1, 101
 Fluorescent in situ hybridization (FISH) analysis, 189, 192, 193, 200
 Fluorochrome labeling, 291
 Focused parathyroidectomy, 239
 Forteo, 321, 323, 326, 328, 341
 Fractional excretion of Mg²⁺, 63
 Fracture risk, 251, 340
 Frameshift mutations, 357
 Free Mg²⁺ ions, 61
 Furin, 37, 167

G

G α 11, 37, 40, 160, 161
 Gain-of-function, 13, 169–171
 Gain-of-function missense mutations, 171
 Ganglia calcifications, 148–149, 156, 160, 162, 171, 209, 307, 316, 347, 357
 G α ₁₁ protein, 171
 Gastrointestinal (GI) dysfunction, 281
 GATA3, 8, 11, 13, 144, 146, 157, 159, 160, 172, 199, 200, 206–210
 G $\beta\gamma$, 89, 90
 Geen fluorescent protein (GFP), 100
 Gene encoding G α (GNAS), 9, 89–94, 345–347, 349, 350, 355, 358, 360, 364–365
 antisense exons 4 and 5, 367
 gene, 357, 373, 377, 380
 locus, 9, 90–93, 346, 363, 365, 367–369, 374, 377, 380, 381, 385
 methylation, 93, 351, 357, 360, 363–369
 methylation analysis, 360
 Gene expression, 14, 21, 33, 41–42, 73, 74, 93, 105, 143, 208, 221
 Genetic defects responsible for hypoparathyroidism, 8
 Genetic disorder, 139, 140, 189, 215, 333, 360
 Genetic/epigenetic testing, 192, 350, 373–385
 Gene transcription, 19, 22, 53, 55, 70, 112, 133, 145, 221, 346
 Genital tract, 209
 Genome-wide association study (GWAS), 210
 Genomic imprinting, 357, 358, 374, 380, 383, 384
 Genotype-phenotype correlation, 350, 357
 Glandulae parathyroideae, 3
 Gley, E., 5
 Glial cells missing-2(GCM2), 8, 11–16, 135, 157, 168, 171–172, 210, 261
 Glial cells missing (GCM), 12, 171, 172
 Glial cells missing homologue B (GCMB) gene, 144, 145, 160, 171, 210
 Glomerular filtration rate (GFR), 50, 55, 63, 103, 119, 158, 314, 315
 Glucagon, 82, 84, 349, 357
 Glucocorticoids, 274, 275, 299, 309
 Glucosuria, 261
 GNAS-AS1 (GNAS antisense transcript), 90–93
 Golgi, 37, 42
 Golgi apparatus, 19, 42, 167
 Golgi complex, 220
 Gonadotropins, 162, 254, 346, 347, 349, 351, 357–361, 384
 GP1Bb, 194
 G protein activity, 364, 365
 G protein α subunit (G α 11), 160
 G protein, α -subunit of the stimulatory, 89, 345
 G protein-coupled receptor (GPCR), 21, 22, 38
 G protein subclasses, 70
 Gq-/G₁₁-dependent signaling, 369
 Granulocyte-colony stimulating factor (G-CSF), 118
 Granulomatosis, 272–273
 Graves's disease (GD), 141, 180, 183, 233, 236, 272, 283

Growth hormone deficiency, 217, 218, 227, 275, 357, 359, 369
 Growth hormone-releasing hormone (GHRH), 346, 347, 349, 351, 357, 359, 365, 369
 Growth plate chondrocytes, 21, 99–100, 360, 392
 Growth retardation, 92, 216, 217, 227, 276, 326, 393
 G α , 89–94, 157, 345, 355, 357–360, 364–369, 373, 374, 377, 380–383
 G α -L and G α -S, 90
 G α mutations, 89, 364
 G α -N1, 90
 Gs, Gq/11, and G12/13, 70
 GTP hydrolase, 89, 90
 Guanine-binding protein G11, 9
 Guanine nucleotide-binding proteins (G proteins), 37, 39, 64, 65, 70, 81, 83, 85, 89–94, 102, 168, 345, 346, 364, 373, 392
 Gut, 22, 61, 62, 69, 206, 232, 324, 397

H

Hair follicles, 23, 111
 Hansen, A., 7
 Haploinsufficiency, 146, 172, 194, 199, 200, 210, 360
 Hashimoto's thyroiditis, 143, 177, 185, 273
 Haversian canal, 293, 338
 HDR. *See* Hypoparathyroidism, deafness, and renal dysplasia (HDR)
 Heart failure, 116, 155, 156, 190, 233, 313, 316
 Hedgehog, 360
 Height, 216, 219, 325, 347
 HEK293 cells, 38, 181–184
 Hematopoietic stem cells (HSCs), 101, 117–121, 200
 Hemochromatosis, 27, 143, 159–161, 272–274
 Heparan sulfate (HS), 74
 Heptahelical, 84
 Heterotopic ossifications, 347, 351
 Heterotrimeric G proteins, 65, 81, 89–90, 102, 346
 Heterozygous mutations, 169, 199, 215, 218, 220, 276, 357, 359, 375, 378, 382, 383, 389, 393, 394
 Heterozygous mutations, GNAS gene at 20q13, 357
 High arched palate, 190
 High-resolution pQCT, 291
 High-resolution ultrasonography, 241
 Histomorphometric, 27, 289, 290, 292, 337–340
 Histomorphometric analysis, 27, 287, 295
 Histomorphometric study, 287, 292
 Histomorphometry, 149, 162, 251, 287–295
 HLA-A*26:01, 185
 HLA-DRB1*01, 185
 HLA-DRB1*09, 185
 Homeostasis, 99, 171
 Homeostatic, 33–35, 61, 304
 Homozygous/compound heterozygous mutations, 215, 389
 Hormonal resistance, 279, 350, 364, 367, 375, 376, 382, 383
 Horsley, V., 5
 Hospitalization, 27, 139, 140, 146, 150, 238, 326, 340

- Hot acid, 7, 8
 Hot hydrochloric acid extracts, 6
 24-Hour urinary calcium excretion, 69, 147, 158, 315
 24-Hour urine collections, 158, 400
Hoxa3, 12, 14, 261
 HSCs. *See* Hematopoietic stem cells (HSCs)
 Human leukocyte antigen (HLA) specificities, 185
 Humoral hypercalcemia of malignancy, 19, 20, 114, 116
 Hungry bone syndrome, 232, 239, 242, 279, 283, 284
 Hydrochlorothiazide, 257, 306, 307, 315
 Hydroxyapatite crystals, 69, 70, 397
 1 α -Hydroxylase activity, 28, 155
 1- α -Hydroxylase enzyme (CYP27B1), 51
 25-Hydroxyvitamin D3 (25(OH)D3), 25, 103
 25-Hydroxyvitamin D (25(OH)D), 22, 27, 28, 70, 71, 133, 252, 253, 255, 257, 272, 279, 298, 301, 305, 306, 308, 310, 324, 327, 347, 356, 359, 398
 25-Hydroxyvitamin D-1 α hydroxylase [1(OH)ase], 53, 70
 25-Hydroxyvitamin D 1-alpha-hydroxylase, 70, 232, 347
 25-Hydroxyvitamin D deficiency, 356
 Hyperaldosteronism, 121, 171, 227
 Hypercalcemia
 fetal, 251, 260, 261
 of malignancy, 8, 253, 260
 malignant, 111, 112
 maternal, 250, 257, 259, 260, 271, 275–276
 non-parathyroid, 27–28
 Hypercalciuria, 9, 40, 64, 105, 143, 147, 149, 170, 218, 232, 251, 256, 257, 272, 280, 282–284, 301, 306, 327, 328, 333, 336, 337, 348, 361, 398
 Hypermagnesemia, 63–65, 140, 144, 232, 260, 398, 400
 Hyperparathyroid bone disease, 369
 Hyperparathyroidism
 maternal, 157, 160, 275, 276
 neonatal severe, 64, 169
 recurrent primary, 241
 Hyperphagia, 359
 Hyperphosphatemia, 36, 52, 71, 73, 149, 157, 158, 161, 167, 217, 252, 260–262, 279, 307, 319, 345–347, 349, 356, 359, 360, 363–369, 389
 Hyperphosphatemic subjects, 300
 Hyperreninemia, 171
 Hypertelorism, 190, 205, 355
 Hyperthyroidism, 141, 232, 236–237, 271, 272, 283
 Hypocalcemia
 maternal, 249, 256, 258
 neonatal, 157, 190, 259–261, 275, 276, 279, 326
 refractory, 279
 transient, 236, 239, 242
 Hypocalcemic, patients, 73
 Hypocalcemic tetany, 4, 227
 Hypocalciuric values, 253
 Hypogonadism, 142, 159, 162, 220, 227, 274, 281, 349, 359
 Hypokalemic alkalosis, 171
 Hypomagnesemia, 27, 62–65, 121, 157, 158, 160, 161, 201, 209, 218, 219, 232, 236, 261, 275, 276, 279, 284, 300, 303, 304, 307, 309, 319, 324, 326, 328, 397–400
 Hypomineralization, 219
 Hypoparathyroid, 6, 140, 148, 149, 158, 161, 169, 170, 180, 181, 183, 250, 253, 256–258, 261, 262, 273, 287, 288, 290, 293, 295, 310, 315, 316, 320, 327, 328, 334–336
 Hypoparathyroidism, 279
 autoimmune, 140, 142–143, 150, 160, 177–186, 272, 322, 324
 during lactation, 249–262
 during pregnancy, 249–262
 transient, 142, 157, 160, 238, 239, 243, 275
 Hypoparathyroidism Association, 317, 407, 409–413
 Hypoparathyroidism, deafness, and renal dysplasia (HDR), 146, 159, 162, 199–210
 Hypoparathyroid subjects, 27, 287–290, 301, 336, 337, 340
 Hypopharyngo-esophagectomy, 242–243
 Hypophosphatemia, 35, 36, 52, 54, 55, 104, 232
 Hypoplastic teeth, 316
 Hypothyroidism, 159, 190, 226, 227, 273, 274, 349, 357, 359
- I**
 Idiopathic hypoparathyroid, 181, 183
 Idiopathic hypoparathyroidism, 4, 7, 143, 144, 148, 149, 169, 177, 179–181, 183, 185, 195, 281, 282, 307, 320, 322, 363
 Idiopathic thrombocytopenia purpura, 191
 IGF, 103
 IGF-I, 103, 217
 Ileum, 61
 Iliac crest bone biopsies, 149, 287, 289, 295, 337, 338
 Immortal, 130, 133
 Immunization with live vaccines, 194
 Immunoassays, 4, 8
 Immunoblotting, 181, 182
 Immunodeficiency disease, 191
 Immunoheterogeneity, 25
 Immunoradiometric assay (IRMA), 25, 35, 41
 Impaired PTH signaling in renal proximal tubules, 359
 Impaired renal function, 51, 53, 145, 282, 315
 Imprinted genomic loci, 367
 Imprinted G α expression, 369
 Imprinted mode of inheritance, 367
 Imprinting, 89–94, 350, 351, 373, 377, 380, 384
 Imprinting control elements (ICEs), 380, 381
 Inactivating mutation, calcium-sensing receptor (CaSR), 39–40, 64, 276
 Incidence, 117, 139, 141–146, 150, 189, 216, 233, 234, 236–241, 243, 261, 275, 336
 Indian rhinoceros, 4
 Indirect immunofluorescence, 177, 180, 181
 Infants, 145, 157, 190, 216, 259, 261, 280, 301, 326, 329, 359, 389, 390, 393, 394
 Inferior thyroid artery, 231, 237
 Infiltration, 27, 161, 179, 180, 240, 272, 273

Infiltrative disorders, 139, 160, 161, 271
 Injectable PTH therapy, 295
 Innate immunity, 121
 Inorganic phosphate (Pi), 49–52, 54, 56, 81, 149
 Inositol phosphate accumulation, 183
 Inositol trisphosphate (IP₃), 38, 81, 85, 366, 369
 Insulator, 94
 Insulin secretion, 23, 120
 Intact/bio-intact PTH, 28, 41, 114, 141, 142, 158, 159, 163, 250, 252, 253, 280
 Interleukin 1 β , 40, 275
 Interleukin 6, 40, 275
 Intermittent injection, 101
 Internalization vesicles, 85
 Interrupted aortic arch, 190
 Intestinal absorption, 50, 52, 61, 75, 282, 307
 Intestinal calcium absorption, 35, 51, 55, 71, 75, 155, 158, 232, 236, 250, 251, 253, 255–257, 262, 309, 359
 Intestinal epithelium, 69, 319
 Intestine, 34, 35, 40, 50, 51, 69, 71, 74, 75, 252, 253, 255, 304, 347, 397, 401
 Intracellular cation, 61, 397
 Intracellular compartment, 61
 Intracellular degradation, 21, 33, 35, 36, 44, 70, 117
 Intracellular Mg²⁺ depletion, 62, 65
 Intracranial calcification, 148, 149, 205, 209
 Intracrine, 23, 70, 71, 112, 119, 121
 Intraoperative PTH (IOPTH), 239, 240, 242
 assay, 238
 monitoring, 238, 241, 242
 Intratrabecular tunneling, 337–339
 Intrauterine growth restriction (IUGR), 216, 218, 219, 376
 Intravenous infusion (IV), calcium gluconate, 308, 313
 Intronic/constitutional deletions, 364
 Introns, 19, 20, 90, 91, 169, 368
 Iodine 131, 271, 272
 Iodine-131 therapy, 144, 161, 271
 Ionized/albumin-corrected calcium, 256
 Ionized calcium, 21, 155–157, 163, 249, 253, 255, 256, 260, 275, 280, 297, 298, 306, 315, 326, 334
 Ionized fraction, 314
 IP₃. *See* Inositol trisphosphate (IP₃)
 Iron
 accumulation of, 143, 161
 overload, 160, 274
 Isolated hypoparathyroidism, 144, 145, 169, 208, 282

J
 Jansen metaphyseal chondrodysplasia (JMC), 389, 393
 Jansen's chondrodysplasia, 85
 Jansen's diseases, 365
 Jejunum, 50
 c-Jun N-terminal kinase (JNK), 39, 120

K
 Kearns–Sayre syndrome, 144, 146, 161, 226–228

Kenny–Caffey syndrome, 27, 145, 160, 215–222
 Keratinization, 23
 Keratinocytes, 21–23, 121, 220
 differentiation, 23
 KH Splicing regulatory protein (KSRP), 42
 Kidney, 8, 21, 22, 26, 28, 34, 40, 41, 51, 52, 61, 63, 69–71, 74–76, 81, 85, 93, 99–105, 115, 117–120, 146, 158, 162, 199–203, 208, 209, 226, 232, 250, 255, 275, 276, 280, 303, 319, 320, 324, 326, 347, 377, 392, 397, 399, 401, 412
 KIDOQI clinical practice guidelines, 28
 Klotho-FGFR-1, 57
 Knock-in, 85, 393
 Knockout mouse, 91, 100, 103, 172, 209–210, 359

L

Lactation, 23, 111, 249–262
 Lactose, 255, 282
 L-amino acids (particularly aromatic amino acids), 40
 Large carboxyl-terminal fragments, partial N-structure, 28
 Laryngectomy, 242–243
 Laryngospasm, 146, 155, 156, 159, 233, 407
 Late endosomes, 220
 Ligand-binding pocket, 84
 Ligation, thyroidal arteries, 231, 237
 Ligature of the main trunk, inferior thyroideal artery, 237
 Lilly, 7
 12-and 15-Lipoxygenase pathways, 40
 Lithium, 64
 Lithium chloride, 133
 LOI. *See* Loss of imprinting (LOI)
 Long-acting analog, 85
 Long-acting form of parathyroid hormone (LA-PTH), 9, 85
 Loop diuretics, 306, 309, 398, 400, 401
 Loss of function, 8, 13, 14, 157, 160, 169, 172, 221, 374, 378, 380, 383–384
 Loss of heterozygosity (LOH), 381
 Loss of imprinting (LOI), 375, 376, 378, 380, 381, 384, 385
 Loss of interaction, 206, 208
 Loss of methylation, 92, 360, 367, 369, 380, 381
 Low turnover, 294
 LRP5, 101
 LRP6, 102
 Lumbar spine, 27, 251, 337
 Lymph node dissection, 236
 Lymph node neck dissection, 231
 Lymphocytes, 22, 191, 195, 400
 Lymphocytic and plasma cell infiltration, 179

M

MacCallum, W.G., 6
 Macrocephaly, 218, 219
 Magnesium

- absorption, 397
 - deficiency, 21, 143–144, 275, 280, 281, 397–401
 - infusions (tocolytic therapy), 40, 64, 260
 - preparations, 401
 - repletion, 400, 401
 - supplementation, 261, 275, 319, 324, 401
 - Magnesium (Mg^{2+}) homeostasis, 61–62, 65, 303, 399, 401
 - Major outflow tract defect, heart, 191–192
 - Malabsorption, 281
 - Malabsorption syndromes, 63, 401
 - Mammary gland, 21, 111, 113, 253, 308, 389, 392
 - Management plan, 258, 299
 - MAPKs. *See* Mitogen-activated protein kinases (MAPKs)
 - Markers, bone formation, 251
 - Marrow star volume, 287
 - Massachusetts General Hospital (MGH), 7
 - Maternal allele, 90, 357, 358, 360, 365, 366, 369, 374, 377, 380, 393
 - Maternal diabetes, 260–261
 - Maternal hyperparathyroidism, 157, 160, 275, 276
 - Maternal hypocalcemia, 249, 256, 258
 - Maternal inheritance, 92, 225, 226, 350
 - Maternally-inherited pattern, 350
 - Matrix extracellular phosphoglycoprotein (MEPE), 51, 72
 - Mechanical stretching, 23
 - Mechanosensitivity, 295
 - MELAS. *See* Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)
 - MEN 1. *See* Multiple endocrine neoplasia type 1 (MEN 1)
 - MEN 2A syndrome, 242
 - Mendelian inheritance, 167, 168, 192
 - Mental retardation, 145, 156, 160, 209, 216, 218, 275, 345, 347, 351, 355, 383
 - Mesenchymal stem cells, 70, 135
 - Metabolic bone disease, 149, 334
 - Metal overload, 272
 - Metastatic disease, 139, 144
 - Microarchitecture, 255, 294, 316
 - Microcephaly, 145, 216, 218, 219
 - Microcomputed tomography (microCT), 27, 290, 293, 294, 337, 339
 - Microcornea, 216
 - microCT. *See* Microcomputed tomography (microCT)
 - Microencapsulation, 134
 - Micrognathia, 190, 216, 218, 219, 389, 392
 - Micropenis, 216, 219
 - Microphthalmia, 145, 215, 216
 - microRNA (miR399), 55
 - Microsatellites, 200, 367, 381
 - Mineral ion homeostasis, 33–36, 103, 319, 363
 - Mineralization density, 295
 - Mineralizing surface (MS), 27, 149, 287, 288, 291, 292, 338
 - Minimally invasive video-assisted thyroidectomy (MIVAT), 238
 - Missense mutations, 72, 169, 171, 199, 200, 206–208, 220, 221, 350, 357, 382, 383, 393
 - Mitochondrial diseases, 225–228
 - Mitochondrial disorders, 144, 160, 161, 225–228
 - Mitochondrial DNA (mtDNA), 140, 146, 225–228
 - Mitochondrial dysfunction, 146, 228
 - Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), 146, 161, 226–228
 - Mitochondrial hypoparathyroidism, 227–228
 - Mitochondrial trifunctional protein deficiency (MTPDS), 144, 146, 161, 228
 - Mitogen-activated protein kinases (MAPKs), 39, 73, 82, 85, 132, 181, 183
 - Molecular biology, 4, 8–9
 - Monoallelic, 92, 374, 384
 - Mortality, 5, 116, 120, 139, 140, 149–150, 216, 218, 252, 259
 - Mother-to-son transmission, 219
 - Mouse-genetics, 192
 - mRNA stability, 22, 41
 - Multihormonal resistance, 350, 356, 358, 360
 - Multiple blood transfusions, 274
 - Multiple endocrine neoplasia type 1 (MEN 1), 237, 241, 283
 - Multiplex ligation-dependent probe amplification (MLPA), 192, 377, 380
 - Multiplex long-range PCR, 381
 - Muscle cramps/cramping, 155, 156, 159, 233, 319
 - Muscle spasms, 63, 159, 162, 298, 333, 347
 - Myoclonic epilepsy with ragged red fibers (MERRF), 226
- N**
- Na^+/Ca^{2+} exchanger (NCX1), 70, 105
 - NACHT leucine-rich repeat protein 5 (NALP5), 142, 184–186
 - autoantibodies, 184–185
 - NALP5. *See* NACHT leucine-rich repeat protein 5 (NALP5)
 - NALP5-specific autoantibodies, 184
 - NaPi2a, 50, 51, 74, 75
 - NaPi2b, 50, 71
 - Na-Pi 2c, 51, 70, 74
 - Nasal bossing, 190
 - NCX1. *See* Na^+/Ca^{2+} exchanger (NCX1)
 - Neck operations, 231, 233
 - Neck surgery, 139–141, 156, 158, 160, 183, 301, 319, 333
 - Neonatal death, 258, 259, 389
 - Neonatal hypocalcemia, 157, 190, 259–261, 275, 276, 279, 326
 - Neonatal hypoparathyroidism, 259–262
 - Neonate, 23, 157, 201–204, 219, 249, 254–256, 259–262, 301, 389

- Nephrocalcinosis, 9, 62–64, 147, 162, 170, 205, 209, 218, 256, 275, 282, 283, 301, 315, 316, 327, 333, 336
 Nephrolithiasis, 104, 105, 147, 162, 170, 301, 315, 333, 336
 Nephron, 62, 103, 105, 119, 155, 169, 171, 359
 NESP55. *See* Neuroendocrine secretory protein 55 (NESP55)
 Nespas, 92, 93
 Neural crest cells (NCCs), 12–14, 64, 194
 Neurocognitive abnormalities, 355
 Neuroendocrine secretory protein 55 (NESP55), 90–93, 367, 369, 374
 Neuromuscular excitability, 63, 233, 284, 298, 299, 304
 Neuromuscular irritability, 155–157, 159, 162, 299, 319, 326, 333, 408
 Neuromuscular symptoms, 155, 170, 298
 Neuropsychological dysfunction, 148
 NHERF proteins, 85
 Nitric oxide, 115
 Noggin, 14
 Noncoding RNAs, 92, 210
 Non-consanguineous, 215, 390, 393
 Non-parathyroid hypercalcemia, 27–28
 Nordenström, J., 4, 5
 Normal subjects, 21, 35, 41, 271, 284, 336, 398
 Normocalcemia, 34, 35, 41, 141, 231, 239, 257, 258, 283, 303, 305, 306, 334, 335, 345, 347, 369, 399
 Normocalcemic hypoparathyroidism, 140, 141, 377
 Npt2a, 104
 Npt2c, 104
 N-PTH, 25, 26, 28
 NR4A2 (Nurr1), 103
 N-terminal fragments, 21, 112, 114
 Nuclear localization signal (NLS), 22, 23, 112, 114, 115, 119, 206
 Nucleic acid metabolism, 49
 26-Nucleotide sequence of PTH mRNA, 3'-UTR, 55
 Null mutations, 220, 357, 360
- O**
- Obesity, 345, 347, 351, 355–361, 363, 374, 383
 Obligate carrier, 367
 Occludin, 62
 Oligodontia, 216, 219
 Olmsted County, 140, 146
 Open-label design, 336
 Oral calcium, 141, 195, 279, 280, 282, 283, 297, 300–301, 308, 309, 314, 333, 361
 Organoids, 134
 Osteitis fibrosa cystica, 239, 348
 Osteoblastic bone resorption and osteoclastogenesis, 22
 Osteoblastic lineage, 70, 72, 99–103
 Osteoblasts, 22, 23, 50–53, 55, 70, 72, 73, 81, 99–103, 117, 118, 121, 135, 143, 254, 360, 392
 Osteocalcin (Oc), 50, 101, 239, 337, 338
 Osteoclast, 23, 50, 51, 53, 71, 102, 112, 143, 347, 390, 392
 Osteoclast-mediated bone resorption, 253, 254
 Osteocraniostenosis (OCS), 215, 219–222
 Osteocyte, 35, 50–53, 70, 72, 73, 99–101, 254, 295
 Osteocytic cells, 73
 Osteocytic osteolysis, 253–255
 Osteoid surface, 288, 338, 339
 Osteopenia, 101, 162, 217, 274
 Osteoporosis, 115, 117, 162, 239, 251, 255, 262, 274, 316, 320, 321, 327, 328
 Osteoprogenitors, 99, 101
 Osteoprotegerin (OPG), 71, 100, 102
 Osteosarcoma, 117, 321, 328
 Osteosarcoma risk, 328, 341
 Osteostatin, 112, 250
 Outwardly rectifying potassium channel, 171
 Owen, R., 4
 Oxytocin (OT), 254, 255
- P**
- 12p12.1-11.2, 20
 p21, 46, 56
 Palate, 145, 157, 189–191, 194, 195
 Pancreas, 21, 23, 111, 120–121
 Pancreatitis, 155, 161, 275, 284, 400
 Paracellular, 50, 61, 64, 71, 171, 319, 397
 Paracellular Ca⁺⁺ transport, 69, 71
 Paracrine, 19–23, 43, 49, 50, 70, 72–74, 81, 89, 99, 101, 111–115, 117, 120, 121, 392
 Paracrine regulator, 20, 21, 43
 Parathormone, 7
 Parathyroid
 adenomas, 129, 131, 132, 134, 143, 171, 177, 232
 autoantibodies, 180, 181, 185, 186
 cancer, 39, 129
 cell line, 28, 130–133
 cells, 15, 16, 19, 26, 33, 37, 38, 40–43, 53, 55, 56, 129–135, 145, 161, 172, 180, 181, 184, 397
 cellular proliferation, 21, 33, 35, 36, 42–44, 53
 function, 15, 21, 26, 27, 33, 35, 36, 38–44, 51–53, 55, 57, 130, 134, 135, 157, 158, 233, 238, 249, 255, 258–259, 262, 275, 304, 305, 307, 310, 327, 328, 341
 organogenesis, 11, 13–16, 271
 Parathyroidectomized animals, 6, 320, 363
 Parathyroidectomy, 6, 7, 73, 105, 121, 232, 237, 239–243, 256, 283
 Parathyroid gland, 3, 5–9, 11–16, 33, 35, 41–43, 53, 55, 56, 64, 70, 72–76, 129, 131–135, 139–145, 156, 157, 159–161, 167–169, 171, 172, 179, 183, 184, 190, 194, 199, 217, 219–221, 231, 232, 236–239, 241, 242, 271–274, 276, 279, 304, 307, 308, 327, 333
 Parathyroid hormone (PTH), 279
 antagonist, 82
 assays, 25–28, 41, 158, 238
 continuous infusion of, 295

- deficiency, 227, 287, 315, 320
 fragments, 25, 28, 41, 82
 normal PTH levels, 272
 preformed, 33, 35
 prepro PTH, 19, 36, 37, 42, 169
 preproPTH gene, 19, 33, 35, 41, 42
 preproPTH mRNA, 21, 26, 36, 37, 41, 42, 167, 169
 proPTH, 37, 169
 PTH(1-34), 8, 9, 27, 82–86, 117–120, 218, 292, 293, 315, 320–329, 334, 341, 383
 PTH(1-84), 9, 19, 21, 25–28, 33, 35–37, 41, 70, 115–117, 120, 291–294, 315, 333–341
 PTH(7-84), 41
 PTH(15-34), 82, 84
 PTH-KO, 99, 100
 release and secretion, 53
 replacement by continuous subcutaneous infusion, 323–326
 resistance, 92, 157, 161, 162, 276, 346–349, 357, 359–361, 363–365, 369, 377, 383, 389, 394
 secretion, 21, 26, 27, 33–37, 39–41, 44, 49–57, 64, 65, 70, 74–76, 121, 130–132, 134, 135, 140, 143, 144, 155, 157, 161, 169, 180, 183, 184, 210, 231, 232, 279, 284, 307, 310, 320, 398–400
 Parathyroid hormone (PTH) receptor 1 (PTHr1), 20, 22, 41, 70, 73, 81–85, 99–104, 112, 114, 115, 347, 350, 374, 389
 Parathyroiditis, 179, 180, 272, 273
 Parental imprinting, 373, 374
 Parenteral magnesium supplementation, 275
 Paresthesias, 155, 156, 162, 170, 209, 297, 313, 333, 347, 357
 Passive immunization, 179
 Passively, 50, 61
 Paternal allele, 91, 92, 357, 358, 365, 366, 368, 380, 382, 393
 Paternal G α silencing, 92, 93
 Patient advocacy, 410
 PAX1, 12, 14
Pax1, 9, 12
 PDE4D, 350, 351, 373, 375, 376, 382, 383, 385
 Pearson syndrome, 226
PED4D, 383
 Penetrance, 159, 189, 208, 365, 394
 Pericytic cells, 100
 Periplasmic membrane proteins, 55
 Permanent hypoparathyroidism, 141, 142, 217, 236, 259
 Persistent hypoparathyroidism, 233, 236–243
 Pharmacodynamic studies, 334
 Pharyngeal pouches (3rd and 4th), 11, 172
 Phenotype, 12, 15, 40, 72, 85, 90–92, 100, 116, 135, 142, 145, 161–163, 189, 192, 195, 199–205, 208, 209, 216, 219, 220, 226, 261, 262, 346, 350, 351, 359, 361, 373–375, 377, 378, 382–385, 389, 393
 PHEX, 72, 73, 75
 Phosphate
 homeostasis, 19, 22, 33, 35, 36, 49, 363, 364, 392, 399
 loading, 21, 35, 44
 reabsorption, 99, 103, 104, 356
 transporters, 50
 Phosphaturia, 7, 34, 35, 73–76, 104, 105, 364
 Phosphodiesterase, 39, 73, 360, 373, 383
 Phospholipase A2, 55, 56
 Phospholipase C (PLC), 38–40, 64, 70, 81, 82, 85, 102, 103, 392
 Phospholipase C (PLC)-protein kinase C (PKC) pathway, 103
 Phospholipases A2 and D, 39
 Phospholipases C and A2, 64
 Phospholipids, 49
 Phosphoproteins, 49, 104
 Phosphorus, 49–57, 69–70, 74, 99, 133, 141, 146, 148, 149, 157, 158, 163, 232, 250–253, 255, 258, 262, 307, 321, 326, 327, 398
 homeostasis, 99
 Phosphorylation, 55, 85, 102, 104, 105, 114, 183, 373, 397
 Photoaffinity cross-linking, 83
 PHPT. *See* Primary hyperparathyroidism (PHPT)
 Pin-1, 42
 Pit-1 and Pit-2, 50
 Pituitary gland, 365
 PKC. *See* Protein kinase C (PKC)
 PLA2, 40, 56
 Placebo, 293, 334, 336, 337
 Placenta(s), 21, 249–252, 255–260, 262, 275, 389
 Placental lactogen, 256, 257
 Placental mineral transport, 252
 Plasma membrane ATPase (PMCA1b), 69, 71, 105
 Plasma membrane Ca²⁺ ATPase (PMCA1b), 69, 71, 105
 Platelets, 191, 350, 364
 PLC. *See* Phospholipase C (PLC)
 P132L mutation, 393
 p38 MAPK, 39
 PNU TL1, 194
 POH. *See* Progressive osseous heteroplasia (POH)
 POH (severe ectopic ossification), 358
 Point mutation, 144–146, 222, 226, 228, 364, 367, 393
 Polyadenylation cassette, 92, 94
 Polydipsia, 170, 282, 309
 Polyuria, 63, 170, 282, 309
 Population-based studies, 141, 146, 150
 Positive allosteric activators, 38
 Positive balance, 287, 294
 Positive predictive value (PPV), 142, 238
 Positive transepithelial voltage, 62
 Posterior pharyngeal pouches, 11
 Postoperative hypoparathyroidism, 141, 142, 144, 160, 231–243, 303
 Postsurgical hypoparathyroidism, 27, 139, 147, 149, 150, 158–161, 231, 239, 279, 283, 299, 305, 307, 310, 316, 320, 322, 323, 325

- Post-thyroid surgery, 287
 Post-translational control, 22
 Post-translational processing, 20, 21, 112
 Potassium wasting, 400
 PPHP. *See* Pseudopseudohypoparathyroidism (PPHP)
 Pre-eclampsia/eclampsia, 40, 64, 260, 275
 Prefoldin, 220
 Pregnancy, 23, 111, 195, 249–262, 275, 390
 Prenatal diagnosis, 350, 384
 Primary hyperparathyroidism (PHPT), 8, 26–28, 39, 73, 101, 114, 120, 169, 232, 237, 239–242, 259, 260, 271, 275, 283
 Primary hypoparathyroidism, 27, 221, 227, 228, 276, 279, 345, 348, 357, 361
 Primary immunodeficiency, 189, 191
 Primordia, 12, 172
 PRKAR1A, 350, 351, 360, 373, 375–378, 382, 383, 385
 Progenitor, 15, 70, 100, 118, 119, 210
 Programmed cell death (apoptosis), 44, 117
 Progressive external ophthalmoplegia (PEO), 161, 226, 227
 Progressive osseous heteroplasia (POH), 89, 355, 356, 358, 360, 361, 368, 375, 376, 382, 384, 385
 Prolactin, 23, 254, 256, 257, 349, 357
 Proliferating cell nuclear antigen (PCNA), 43
 Proliferation, fetal growth, 392
 Prolonged QT interval, 156
 Promoter competition, 94
 Propeptide, 167, 169
 Proprotein convertases, 72, 167
 Protein-bound, serum, 61
 Protein fold, 83
 Protein kinase A (PKA), 64, 70, 81, 82, 85, 89, 90, 102–105, 115, 120, 347, 364, 366, 369, 373, 374, 377, 382, 392
 Protein kinase C (PKC), 70, 81–82, 85, 103–105, 120, 369, 392
 Protein phosphatase 2B, 42
 Protein sequencing, 8
 Proton pump inhibitors (PPIs), 63, 300, 307, 400
 Proximal convoluted tubule (PCT), 61–63, 70, 103
 Proximal renal tubules, 345, 365, 366, 368, 374
 Proximal tubule, 35, 50, 70, 74, 99, 103, 104, 158, 319, 347, 356, 365, 366, 398
 Pseudoglands, 134
 Pseudohyperparathyroidism
 in mother, 260
 of pregnancy, 250
 Pseudohypoparathyroidism (PHP)
 PHP-Ia/PHP1a, 346, 349–351, 355–361, 363–369, 374–378, 382–385
 PHP-Ib/PHP1b, 89, 90, 92–94, 346, 349–351, 360, 361, 363–369, 375–381, 383–385
 pseudo-PHP, 4, 7
 type I, 348–351, 364
 type II/PHP-II, 348–349, 364, 369
 Pseudohypoparathyroidism 1C (PHP1C), 360, 375–377
 Pseudopseudohypoparathyroidism (PPHP), 89, 92, 345, 346, 349–351, 355–361, 363, 364, 367, 368, 375, 376, 382–385
 Pseudotumor cerebri, 156
 Psychosomatic illness, 407
 PTH gene, 8, 14, 20, 21, 27, 41–42, 70, 74, 133, 140, 143, 145, 156, 160, 167, 169, 199, 250, 256
 PTH(1-84)/large C-PTH fragments, 28
 PTHLH, 11, 375, 376, 382
 PTH mRNA, 28, 35, 53, 55, 133, 169
 PTH mRNA 3'-UTR, 19, 55
 PTH receptor, 100, 103–105, 156, 200, 257, 261, 262, 307, 345, 360, 392
 PTH-related protein (PTHrP)
 PTHrP-KO, 99
 PTHrP receptor, 20, 22, 102, 111, 364–366, 369, 392, 393
 PTH1R gene, 392–394
 PTHrP receptor type 1 (PTHR1), 20, 22, 41, 70, 73, 81–86, 99–104, 114, 115, 347, 350, 374
PTPN22, 185
 PT-r, cell line, 28, 130, 133, 134
- Q**
 22q11.2 deletion, 189, 192, 194, 261
 Quality of life (QoL), 303, 310, 320, 321, 328, 333, 335–336, 412, 413
 Quantitative computed tomography (QCT), 337
 Quantitative genomic PCR, 377, 381
- R**
 Radiation-induced hypoparathyroidism, 272
 Radioimmunoprecipitation, 181–183
 Randomized control study (RCT), 293, 334, 337
 RANKL. *See* Receptor activator of NF-kb ligand (RANKL)
 Rasmussen, H., 8
 Receptor activator of NF-kb ligand (RANKL), 52, 71, 100, 102, 392
 Receptor activator of nuclear factor κ -B, 52, 54, 392
 Receptor blocking activity, 181
 Receptor internalization, 38, 85
 Recombinant PTH1-84, 9, 315
 Recurrent infection, 190, 192, 216
 Recurrent primary hyperparathyroidism, 241
 Redistribution, 62, 90
 Reference range, serum calcium, 300, 336
 Refractory hypocalcemia, 279
 Refractory hypoparathyroidism, 279
 Regulatory proteins, 42, 85
 Regulatory subunit, PKA, 369, 377
 Remodeling activation frequency, 287
 Remodeling cycle, 287, 288
 Renal abnormalities, 145, 200, 208
 Renal anomalies, 159, 162, 199–210
 Renal calcifications, 315, 322, 327, 333
 Renal colic, 315

- Renal dysplasia, 159, 208, 209
 Renal excretion, 36, 50, 61, 158, 232
 Renal failure, 26–28, 119, 199, 209, 273, 274, 279, 282, 300, 315, 336, 356, 401
 Renal imaging, 159, 162, 315
 Renal impairment, 42, 63, 170, 200, 282, 283, 300
 Renal insufficiency, 42, 44, 63, 105, 147, 199, 205, 315, 320, 322, 360
 Renal proximal tubular cells, 51
 Renal proximal tubules, 53, 70, 91, 92, 94, 119, 345, 357–359, 365, 366, 368, 374
 Renal resistance, 284, 356, 377
 Renal tubular magnesium reabsorption, 398, 400
 Renal tubular reabsorption, 22, 253, 306, 398
 Renal tubule, 65, 120, 144, 171, 232, 333, 336, 337, 345, 365, 366, 368, 374, 400
 Renal ultrasound, 147, 195, 315
 Renal wasting, 398, 399
 Repressor, 94
 Resistance to parathyroid hormone (PTH), 7, 355
 Resorption depth, 287
 Resorption period, 287
 Restriction fragment length polymorphism (RFLP), 167
 Retroperitoneum, 273
 Rho kinase, 39
 rhPTH 1-84, 327
 Riedel's thyroiditis, 273–274
 Risk of fracture, 316, 349
 Runx2/Cbfa1, 55, 102, 115, 120, 360
 Russell-Silver syndrome, 384
- S**
- Sandström, I., 3–9
 Sandwich assays, 8, 41
 Sanjad–Sakati syndromes, 145, 160, 215–222, 326
 Sarcoidosis, 27, 272, 273
 Schmidt's syndrome, 177
 Sclerostin, 50, 101, 102
 Secondary hyperparathyroidism (SHPT), 26, 28, 39, 42–44, 52, 55, 74, 75, 103, 121, 129, 131, 132, 134, 239, 242, 256–258, 283, 359
 Second generation immunoradiometric assays, 41
 Second generation PTH assays, 25, 28
 Secretin, 82
 Secretory vesicles, 19, 36–37, 120, 167
 Seizures, 27, 63, 140, 145–147, 149, 155–157, 159, 161, 170, 171, 190, 209, 216, 226, 233, 259–261, 297, 298, 319, 326, 333, 347, 400
 Sense phosphate concentration, 51, 54–55
 Sensing mechanism for phosphate, 54, 55
 Sensitivity, 34, 75, 92, 100, 130, 131, 134, 135, 142, 170, 171, 183, 200, 238, 298, 300, 310, 328
 Serine residues, 85, 90
 Serum calcium, 26, 53, 73, 85, 129, 139, 141, 142, 147–149, 157, 158, 170, 195, 210, 218, 231, 238, 239, 249, 251–253, 255–262, 271, 274, 275, 280, 282, 297–301, 303–310, 314–317, 319–323, 325–327, 329, 333–336, 347, 373, 408
 concentration, 22, 210, 249, 282, 283, 292–293, 297, 313–315, 320, 333
 ionized calcium, 255
 Serum creatine kinase (CK), 227
 Serum magnesium, 158, 170, 236, 250, 305, 307, 324, 328, 398
 concentrations, 21, 400
 Serum phosphate, 35, 157, 158, 298, 300, 303, 337, 363, 377
 concentrations, 21, 35, 170, 373
 Serum phosphorus level, 50, 307, 327
 Set-point, 26, 27, 35, 37, 81, 134, 161, 275
 Seven transmembrane domain, 81, 82
 Severely deficient in vitamin D, 250, 252, 255, 258
 Severe vitamin D deficiency, 252, 255
 SF36, 335
 Shoemaker's cramp, 5
 Short-bowel syndrome, 63
 Short stature, 145, 160, 162, 215, 218, 219, 225–227, 262, 274, 345, 347, 351, 355–357, 360, 361, 363, 375, 392
 Sigmoidal, 26, 34, 35, 37
 Signalase, 167
 Signal peptide, 20, 22, 111, 112, 119, 169, 170
 Signal transduction, 38, 65, 81, 82, 156, 157, 345, 346, 393
 Silenced, 91, 93, 94, 358, 365, 368
 Single nucleotide polymorphisms (SNP), 367, 381
Six1, 4, 12
 Skeletal homeostasis, 114, 287, 394
 Skeleton, 40, 69, 70, 73, 81, 85, 111, 249–254, 258, 261, 287, 324, 328, 333, 348, 357
 Skin fibroblasts, 364
 Sleep disturbances, 156
 Slit-lamp and ophthalmoscopic examinations, 316
 Smooth muscles, 21, 23, 111, 114, 206
 Sodium, 49, 309, 320, 327, 328, 380
 Sodium/calcium exchanger 1 (NCX1), 70, 105
 Sodium-dependent phosphate cotransporters, 70
 Sodium-dependent phosphate co-transporter type 2A, 81
 Sodium/hydrogen exchanger regulatory factor-1 (NHERF-1), 104, 115
 Sodium-hydrogen exchanger regulatory factor (NHERF), 70, 85
 Sodium-phosphate co-transporters, 50, 52, 54, 69, 70, 104
 Sodium-potassium-chloride cotransporter, 64, 171
 Sonic hedgehog (SHH), 11, 13, 14
 SOX3, 13, 145, 160, 168, 172
 Spasms, 5, 63, 155, 159, 162, 170, 227, 232, 297, 298, 319, 333, 347, 400, 407, 408
 Specificity, 74, 142, 177, 180, 183, 298, 346
 Splice junction, 357
 Spontaneous abortion, 258
 Sporadic, 179, 185, 186, 215, 219, 226–228, 282, 293, 349, 382
 adenoma, 239–241
 PHP-Ib, 350, 367–369

Squamous carcinoma, 22
 Steatorrhea, 63, 142, 281, 400
 Steep inverse sigmoidal relationship, 34, 37
 Stem cells, 70, 101, 117–120, 135, 200
 Sternocleidomastoid muscle, 237
 Stillbirth, 258, 259
 Stored PTH, 19, 33, 36, 37, 41
 Stridor, 155, 156, 159, 313
 Stromal cells, 55, 91, 101, 102, 117
 Structure-function, 199, 206–208, 210
 Stunning, 160, 232
 STX16, 92, 93, 367–369, 375, 381, 385
 Subcutaneous injections of PTH 1-34, 322
 Subcutaneous ossifications, 355, 382
 Subcutaneous tissues, 162, 355
 Sulfate, 61, 74, 260, 300, 401
 Supplemental calcium and vitamin D, 334
 Surgery
 abdominal, 283–284
 cervical, 231
 neck, 139–141, 156, 158, 160, 183, 301, 319, 333
 post-thyroid, 287
 Sweden, 3
 Synthetic human PTH 1-34, 320–327
 Synthetic PTH1-34, 315
 Systemic amyloidosis, 273

T

Tachycardia, 156, 157
 Tartrate-resistant acid phosphatase, 337
 TBX1, 11, 13, 14, 144, 145, 160, 163, 194
 TCBE gene, 14
 T cell reactivity, 179, 180
 T cells, 14, 15, 118, 157, 177, 179–180, 184–186, 189, 191, 206, 209, 217, 218
 Temporary ischemia, 232
 Teriparatide, 301, 321
 Terminus, 19, 22, 41, 90, 377, 382
 Tetany, 4–7, 63, 155–157, 159, 190, 209, 227, 233, 237, 252, 259, 260, 275, 297, 298, 308, 313, 319, 347, 357, 407, 408
 Tetralogy of Fallot, 157, 190, 191
 TGF- β , 102, 273
 Thalassemia, 27, 143, 160, 161, 274
 Theodor Billroth, 5
 Therapeutic test, 401
 Thiazide diuretics, 170, 288, 306, 315, 327
 Thiazides, 170, 218, 257, 284, 288, 301, 306, 315, 322, 327, 328
 Thick ascending limb (TAL), 34, 61, 171, 319, 347, 348, 359, 398
 Third, fourth, and fifth metacarpals and metatarsals, 355
 Third generation assays, 41
 Third generation drug, 39
 Third generation PTH assays, 25, 28
 Three-dimensional cell cultures, 134, 135
 Three-dimensional in vitro cell culture models, 134
 Three generations, 25, 28

Thymic aplasia, 145, 191
 Thymus, 11–16, 142, 156, 157, 160, 172, 177, 190, 191, 194, 195, 209, 210
 Thymus gland, 11, 16, 142, 191
 Thyroid
 autoimmunity, 177, 179, 181
 carcinoma, 236
 surgery, 5, 6, 141, 233, 242, 287, 304, 322
 Thyroidectomy, 5, 73, 141, 232, 234–239, 243, 283, 284
 Thyroid glands
 accessory, 3
 autoimmune diseases, 191
 Thyroid-stimulating hormone (TSH), 135, 180, 346, 347, 349–351, 357, 359–361, 365, 369, 374, 378, 383, 384
 Thyrotropin, 162, 357
 Tight junctions, 62, 69
 Tingling in the hands and feet, 233
 T-lymphocytes, 118, 186, 191, 195, 273
 Tooth, 6, 23, 111, 316, 389, 394
 Total hip BMD, 337
 Total lobectomy, 236
 Total parathyroidectomy (TPTX), 237, 241, 242, 256, 283
 Total serum calcium concentrations, 249, 314
 Total thyroidectomy, 5, 141, 235, 236, 238, 243
 Trabecular bone, 101, 251, 293
 Trabecular bone mineral content, 254
 Trabecular connectivity, 290
 Trabecular number, 27, 288, 290, 291, 293, 339
 Trabecular plates, 290
 Trabecular rods, 290
 Trabecular separation, 293
 Trabecular spacing, 288
 Trabecular star volume, 287
 Trabecular thickness, 27, 287, 290, 293, 337, 339
 Trabecular tunneling, 293, 340
 Trabecular width, 27, 149, 288, 291, 293, 339
 Transactivates, 43, 172
 Transactivation, 172, 206–208
 Transcellular Ca⁺⁺ transport, 69
 Transcellularly, 61
 Transcription
 factors, 11–14, 55, 73, 81, 102–104, 133, 140, 142, 146, 159, 160, 172, 194, 199, 200, 210
 interference, 94
 Transdifferentiate, 15
 Transepithelial electrochemical gradient, 171
 Transforming growth factor- α (TGF- α), 43, 56, 57
 Transient osteoporosis, hip, 51
 Transient postoperative hypoparathyroidism, 141, 142
 Transient receptor potential melastatin subtype 6 (TRPM6), 61–64, 397
 Transient receptor potential vanilloid 5 (TRPV5), 70, 105
 Translocation, 145, 169, 199, 200
 Transmembrane domain (TMD), 38–40, 81–84, 169, 393
 7 Transmembrane helices, 38, 39, 170
 7 Transmembrane spanning domains, 22
 Treatment

goal, 257
 target, 256
 Tremors, 190, 226
 Trisomy, 381
 Trophoblast, 23
 Trousseau, 156, 159, 233, 298, 408
 Trousseau's signs, 156, 159, 233, 298
 TRPV6, 69, 71, 347
 Truncus arteriosus, 157, 190, 194
 TSH/calcitonin resistance, 369, 384
 Tuberculosis, 121, 272, 273
 Tubulin folding cofactor E (TBCE), 144, 160, 215, 218, 220–222
 Tunneling resorption, 291, 294
 Turner's syndrome, 360
 Twitching, 155, 156, 159, 298
 Two-antibody "intact" sandwich assays for PTH, 41
 Two-site model, 83
 Type III sodium-phosphate transporter, 149
 Type II sodium/phosphate cotransporters, 104

U

Ultrasound, 147, 162, 163, 195, 251, 315, 316
 Umbilical cord, 118, 135, 255
 Underdeveloped chin, 190
 Unilateral thyroid lobectomy, 236
 Uniparental disomy (UPD), 381, 384
 Untranslated region (UTR)
 3' UTR, 19, 20, 41, 42, 55, 90
 5' UTR, 20
 Uppsala, 3
 Upstream of N-ras (Unr), 42
 Urinary calcium excretion, 144, 158, 170, 251, 301, 303, 313–315, 321, 324, 336–337, 366

V

Variability, 12, 144, 183, 189, 192, 199, 208, 209, 256, 258, 259, 349, 400
 Vascular smooth muscle cells (VSMC), 114, 115
 Vascular spasm, 232
 Vascular tone, 23, 103
 Vasoconstrictor, 23, 114
 Vassale and Generali, 4, 5
 VDIR, 104
 VEGF, 115, 118, 119, 233
 Velo-cardio-facial syndrome, 145, 189

Venus flytrap (VFT), 38, 39
 Venus-flytrap-like domain, 169
 Vertebral compression fractures, 255
 Vertebral crush fractures, 251
 Vitamin D
 analogs, 147, 218, 257, 279, 412
 analogues, 301, 303–306, 308, 309, 319, 320
 binding protein, 71, 308
 deficiency, 27, 28, 42, 44, 121, 157, 158, 161, 232, 239, 252, 255, 258, 276, 279, 281, 300, 324, 347, 348, 360, 369, 377
 responsive elements, 71
 supplementation, 28, 140, 148, 315, 324, 333, 335, 338
 therapy, 170, 272, 281, 283, 284, 314, 315, 334
 Vitamin D3, 71, 282, 283, 300, 305, 324, 327
 Vitamin D-dependent calcium binding protein 9K (CaBPD9), 71
 Vitamin D receptor (VDR), 26, 40, 52–55, 57, 70–74, 103, 104, 155, 250, 252, 255, 259, 305
 Vitiligo, 142, 159, 178, 191, 281
 Voegtlin, Carl, 6
 Voltage-gated chloride channel, 171

W

Wall thickness, 287
 WDR14, 194
 Weight, 19, 39, 49, 72, 216, 220, 276, 300, 301, 323, 325, 326, 389
 William Beaumont Regional Medical Center (WBRMC), 408
 Wilson's disease, 27, 143, 159–161, 272–274
 With trabecular number, 288
 Wnt- β catenin, 360
 Wnt signaling, 101, 102, 117

X

Xenopus laevis oocytes, 38
 X-linked inheritance, 167
 X-linked recessive, 144, 145, 160, 168, 172, 284
 X-linked recessive hypoparathyroidism, 145, 172
 X-ray crystallographic, 82

Z

Zinc-finger, 142, 159, 172, 199, 200, 206–208